CN Patent

CN105646452B — 一种蛋白激酶抑制剂的合成方法

Assigned to BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co Ltd · Expires 2018-05-01 · 8y expired

What this patent protects

本发明涉及一种蛋白激酶抑制剂的合成方法，以2‑(异丙基磺酰基)苯胺、2，4，5‑三氯嘧啶及5‑甲基‑2‑异丙氧基‑4‑(4‑吡啶基)苯胺(4)为起始原料，一锅法发生反应，制备得到5‑氯‑N4‑[2‑[(1‑甲基乙基)磺酰基]苯基]‑N2‑[5‑甲基‑2‑(1‑甲基乙氧基)‑4‑(4‑吡啶基)苯基]‑2，4‑嘧啶二胺；在二氧化铂的催化下加氢还原，得到最终化合物色瑞替尼。此制备方法简便易行、收率高，质量好，便于工业化生产。

USPTO Abstract

本发明涉及一种蛋白激酶抑制剂的合成方法，以2‑(异丙基磺酰基)苯胺、2，4，5‑三氯嘧啶及5‑甲基‑2‑异丙氧基‑4‑(4‑吡啶基)苯胺(4)为起始原料，一锅法发生反应，制备得到5‑氯‑N4‑[2‑[(1‑甲基乙基)磺酰基]苯基]‑N2‑[5‑甲基‑2‑(1‑甲基乙氧基)‑4‑(4‑吡啶基)苯基]‑2，4‑嘧啶二胺；在二氧化铂的催化下加氢还原，得到最终化合物色瑞替尼。此制备方法简便易行、收率高，质量好，便于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN105646452B
Jurisdiction
CN
Classification
—
Expires
2018-05-01
Drug substance claim
No
Drug product claim
No
Assignee
BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.